Frontlight ResearchEarly access
CompletedPhase 2
A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria
Key facts
- Who runs it
- Taiho Pharmaceutical Co., Ltd.
- Where
- Japan12 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 126 people enrolled
- Started
- 28 Jun 2022
- Ended
- 22 Dec 2023
- Type of study
- Interventional, 6 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- TAS5315 Dose 1
- TAS5315 Dose 2
- TAS5315 Dose 3
- TAS5315 Dose 4
- TAS5315 Dose 5
- Placebo
- Record updated
- 7 August 2024
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Aged 18 to 75 years
- Diagnosis of chronic spontaneous urticaria (CSU)
- Presence of itch and hives for at least 6 consecutive weeks prior to screening in spite of use of non-sedating H1-antihistamines for CSU
- UAS7 score ≥ 16 and HSS7 score ≥ 8 during 7 days prior to study entry
- In-clinic UAS ≥ 4 on study entry
- Willing and able to complete and Participate Daily for the duration of the study
Who cannot take part
- Treatment with omalizumab or other humanized anti-human IgE monoclonal antibody therapies used to treat CSU within 4 months prior to screening
- Nonresponse to omalizumab or other humanized anti-human IgE monoclonal antibody therapies
- Have been treated with other Bruton's Tyrosine Kinase inhibitors
- Diseases other than CSU with symptoms of urticaria or angioedema, including urticarial vasculitis, erythema multiforme, mastocytosis, or hereditary or acquired angioedema
- Atopic dermatitis, psoriasis, ichthyosis, or other skin disease associated with chronic itching
- Bleeding diathesis
- Uncontrolled hypertension disease states
- Pregnant or lactating women
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the efficacy and safety of TAS5315 in chronic spontaneous urticaria patients with an inadequate response to H1-antihistamines
The 6 groups in the trial
- TAS5315 Dose 1Treatment being tested
- TAS5315 Dose 2Treatment being tested
- TAS5315 Dose 3Treatment being tested
- AS5315 Dose 4Treatment being tested
Treatment: TAS5315 Dose 4
- TAS5315 Dose 5Treatment being tested
- PlaceboPlacebo, for comparison
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2a, Randomized, Double-blind, Study of TAS5315 in Chronic Spontaneous Urticaria Patients With an Inadequate Response to H1-antihistamines
- Record updated
- 7 August 2024